Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats

European Journal of Pharmacology

Volumn 557, Issue 1, 2007, Pages 37-43

  Marco, Eva M ^a   Granstrem, Oleg ^c,d   Moreno, Enrique ^a   Llorente, Ricardo ^a   Adriani, Walter ^b   Laviola, Giovanni ^b   Viveros, Maria Paz ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^d GEROPHARM Ltd   (Russian Federation)

Author keywords

Adolescent rats; Cannabinoid CB1 receptor; Hippocampus; mu opioid receptor; Nicotine; Striatum

Indexed keywords

CANNABINOID 1 RECEPTOR; MU OPIATE RECEPTOR AGONIST; NICOTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; FEMALE; HIPPOCAMPUS; LONG TERM EXPOSURE; MALE; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; RECEPTOR BINDING; SEX RATIO; WESTERN BLOTTING;

ANIMALS; BASAL GANGLIA; FEMALE; HIPPOCAMPUS; MALE; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU; TIME FACTORS;

EID: 33846375539     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.11.013     Document Type: Article

References (55)

1. Adriani W., and Laviola G. Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model. Behav. Pharmacol. 15 (2004) 341-352
2. Adriani W., Macri S., Pacifici R., and Laviola G. Peculiar vulnerability to nicotine oral self-administration in mice during early adolescence. Neuropsychopharmacology 27 (2002) 212-224
3. Adriani W., Granstrem O., Macri S., Izykenova G., Dambinova S., and Laviola G. Behavioral and neurochemical vulnerability during adolescence in mice: studies with nicotine. Neuropsychopharmacology 29 (2004) 869-878
4. Adriani W., Deroche-Gamonet V., Le Moal M., Laviola G., and Piazza P.V. Preexposure during or following adolescence differently affects nicotine-rewarding properties in adult rats. Psychopharmacology (Berl) 184 (2006) 382-390
5. Agrawal A., Neale M.C., Prescott C.A., and Kendler K.S. Cannabis and other illicit drugs: comorbid use and abuse/dependence in males and females. Behav. Genet. 34 (2004) 217-228
6. Balerio G.N., Aso E., Berrendero F., Murtra P., and Maldonado R. Delta 9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur. J. Neurosci. 20 (2004) 2737-2748
7. Balerio G.N., Aso E., and Maldonado R. Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl) 181 (2005) 260-269
8. Balerio G.N., Aso E., and Maldonado R. Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl) 184 (2006) 504-513
9. Berrendero F., Mendizabal V., Robledo P., Galeote L., Bilkei-Gorzo A., Zimmer A., and Maldonado R. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J. Neurosci. 25 (2005) 1103-1112
10. Biala G., and Weglinska B. On the mechanism of cross-tolerance between morphine- and nicotine-induced antinociception: involvement of calcium channels. Prog. Neuro-psychopharmacol. Biol. Psychiatry 30 (2006) 15-21
11. Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Vogt L.J., and Sim-Selley L.J. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J. Neurochem. 73 (1999) 2447-2459
12. Chhatwal J.P., Davis M., Maguschak K.A., and Ressler K.J. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30 (2005) 516-524
13. Contet C., Kieffer B.L., and Befort K. Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. 14 (2004) 370-378
14. Davenport K.E., Houdi A.A., and Van Loon G.R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113 (1990) 40-46
15. DuRant R.H., Smith J.A., Kreiter S.R., and Krowchuk D.P. The relationship between early age of onset of initial substance use and engaging in multiple health risk behaviors among young adolescents. Arch. Pediatr. Adolesc. Med. 153 (1999) 286-291
16. Ellickson P.L., Tucker J.S., and Klein D.J. High-risk behaviors associated with early smoking: results from a 5-year follow-up. J. Adolesc. Health 28 (2001) 465-473
17. Escobedo L.G., Reddy M., and DuRant R.H. Relationship between cigarette smoking and health risk and problem behaviors among US adolescents. Arch. Pediatr. Adolesc. Med. 151 (1997) 66-71
18. Faeh D., Viswanathan B., Chiolero A., Warren W., and Bovet P. Clustering of smoking, alcohol drinking and cannabis use in adolescents in a rapidly developing country. BMC Public Health 6 (2006) 169-176
19. Fride E. Endocannabinoids in the central nervous system: from neuronal networks to behavior. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 633-642
20. Galeote L., Kieffer B.L., Maldonado R., and Berrendero F. Mu-opioid receptors are involved in the tolerance to nicotine antinociception. J. Neurochem. 97 (2006) 416-423
21. González S., Cascio M.G., Fernandez-Ruiz J.J., Fezza F., Di Marzo V., and Ramos J.A. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 954 (2002) 73-81
22. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 1932-1936
23. Herz A. Opioid reward mechanisms: a key role in drug abuse?. Can. J. Physiol. Pharm. 76 (1998) 252-258
24. Humfleet G.L., and Haas A.L. Is marijuana use becoming a 'gateway' to nicotine dependence?. Addiction 99 (2004) 5-6
25. Ismail Z., and el-Guebaly N. Nicotine and endogenous opioids: toward specific pharmacotherapy. Can. J. Psychiatry 43 (1998) 37-42
26. Jacobsen, L.K., Pugh, K.R., Constable, R.T., Westerveld, M., Mencl, W.E., in press. Functional correlates of verbal memory dificits emerging during nicotine withdrawal in abstinent adoloscent cannabis users. Biol. Psychiatry. doi:10.1016/j.biopsych.2006.02.014.
27. Kandel D.B., Yamaguchi K., and Chen K. Stages in the progression of drug involvement from adolescence to adulthood: further evidence for the Gateway Theory. J. Stud. Alcohol 53 (1992) 447-457
28. Kelley B.M., and Middaugh L.D. Periadolescent nicotine exposure reduces cocaine reward in adult mice. J. Addict. Dis. 18 (1999) 27-39
29. Klein L.C. Effects of adolescent nicotine exposure on opioid consumption and neuroendocrine responses in adult male and female rats. Exp. Clin. Psychopharmacol. 9 (2001) 251-261
30. Lai S., Lai H., Page J.B., and McCoy C.B. The association between cigarette smoking and drug abuse in the United States. J. Addict. Dis. 19 (2000) 11-24
31. Laviola G., Adriani W., Terranova M.L., and Gerra G. Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci. Biobehav. Rev. 23 (1999) 993-1010
32. Lichtman A.H., Varvel S.A., and Martin B.R. Endocannabinoids in cognition and dependence. Prostaglandins Leukot. Essent. Fatty Acids 66 (2002) 269-285
33. Lynskey M.T., Heath A.C., Bucholz K.K., Slutske W.S., Madden P.A.F., Nelson E.C., Statham D.J., and Martin N.G. Escalation of drug use in early-onset cannabis users vs. co-twin controls. JAMA 289 (2003) 427-433
34. Maldonado R., Valverde O., and Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 29 (2006) 225-232
35. Marco E.M., Llorente R., Perez-Alvarez L., Moreno E., Guaza C., and Viveros M.P. The kappa-opioid receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety. Behav. Brain Res. 163 (2005) 212-218
36. Marco E.M., Llorente R., Moreno E., Biscaia J.M., Guaza C., and Viveros M.P. Adolescent exposure to nicotine modifies acute functional responses to cannabinoid agonists in rats. Behav. Brain Res. 172 (2006) 46-53
37. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgansberger W., Di Marzo V., and Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 (2002) 530-534
38. Parra-Medina D.M., Talavera G., Elder J.P., and Woodruff S.I. Role of cigarette smoking as a gateway drug to alcohol use in Hispanic junior high school students. J. Natl. Cancer Inst. Monogr. 18 (1995) 83-86
39. Patton G.C., Coffey C., Carlin J.B., Sawyer S.M., and Lynskey M. Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 100 (2005) 1518-1525
40. Picciotto M.R., Caldarone B.J., King S.L., and Zachariou V. Nicotinic receptors in the brain. Links between molecular biology and behavior. Neuropsychopharmacology 22 (2000) 451-465
41. Pomerleau O.F. Endogenous opioids and smoking: a review of progress and problems. Psychoneuroendocrinology 23 (1998) 115-130
42. Pryor G.T., Larsen F.F., Husain S., and Braude M.C. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacol. Biochem. Behav. 8 (1978) 295-318
43. Ribeiro S.C., Kennedy S.E., Smith Y.R., Stohler C.S., and Zubieta J.K. Interface of physical and emotional stress regulation through the endogenous opioid system and mu-opioid receptors. Prog. Neuro-psychopharmacol. Biol. Psychiatry 29 (2005) 1264-1280
44. Rubino T., Vigano D., Massi P., and Parolaro D. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J. Neurochem. 75 (2000) 2080-2086
45. Siqueira L.M., and Brook J.S. Tobacco use as a predictor of illicit drug use and drug-related problems in Colombian youth. J. Adolesc. Health. 32 (2003) 50-57
46. Slotkin T.A. Nicotine and the adolescent brain: insights from an animal model. Neurotoxicol. Teratol. 24 (2002) 369-384
47. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 24 (2000) 417-463
48. Torabi M.R., Bailey W.J., and Majd-Jabbari M. Cigarette smoking as a predictor of alcohol and other drug use by children and adolescents: evidence of the "gateway drug effect". J. Sch. Health 63 (1993) 302-306
49. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
50. Valjent E., Mitchell J.M., Besson M.J., Caboche J., and Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br. J. Pharmacol. 135 (2002) 564-578
51. Van der Stelt M., and Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur. J. Pharmacol. 480 (2003) 133-150
52. Viveros, M.P., Marco, E.M., File, S.E., in press. Nicotine and cannaboids: parallels, contrasts and interactions. Neurosci. Biobehav. Rev. doi:10.1016/j.neubiorev.2006.08.002.
53. Walters C.L., Cleck J.N., Kuo Y.C., and Blendy J.A. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46 (2005) 933-943
54. Wetzels J.J., Kremers S.P., Vitoria P.D., and de Vries H. The alcohol-tobacco relationship: a prospective study among adolescents in six European countries. Addiction 98 (2003) 1755-1763
55. Wewers M.E., Dhatt R.K., Snively T.A., and Tejwani G.A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats. Brain Res. 822 (1999) 107-113